ijms-logo

Journal Browser

Journal Browser

Lysosomal Storage Disorders: Pathophysiology, Molecular Mechanism and Therapeutic Strategies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (20 April 2025) | Viewed by 4118

Special Issue Editors


E-Mail Website
Guest Editor
1. Gaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel
2. Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel
Interests: Gaucher disease; pediatric hematology; pediatric thrombosis and hemostasis; platelet disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It gives us pleasure to invite you to submit a paper to the forthcoming Special Issue of the International Journal of Molecular Sciences (IJMS) on Lysosomal Storage Disorders (LSD). This is a continued issue of our successful special issue: https://www.mdpi.com/journal/ijms/special_issues/PMMTS_LSDs.

As 70 inherited metabolic disorders, Lysosomal Storage Disorders are considered rare, as a group, their incidence is about 1:5000, and they are all the more important given the many different types of underlying lysosomal dysfunction. In addition to the accumulation of the unmetabolized substrate (hence the concept of “storage” disorders), there are a variety of cellular and subcellular abnormalities, including endoplasmic reticulum stress, altered lipid trafficking, autophagy, inflammation, and autoimmune responses. Each of these pathological processes, alone or in combination, may lead to the development of novel therapeutic modalities, some of which have already changed natural history and the lives of patients with various diseases, such as Gaucher, Fabry, MPS and others, and in addition, these new treatments, including gene therapy, may also be of relevance to more common disorders, as we have witnessed from the relationship between Gaucher (both patients and carriers) and Parkinson’s diseases.

Prof. Dr. Ari Zimran, Prof. Dr. Shoshana Revel-Vilk and assisting by our Topical Advisory Panel Member Dr. Ambra Del Grosso (NEST, Istituto Nanoscienze-CNR and Scuola Normale Superiore), the Special Issue aims to showcase the latest advancements and innovative research in LSD. Your contribution will help make this a truly comprehensive and valuable resource for the research community. We welcome any high-quality contribution, which could be research articles from basic science to clinical studies, and we also invite reviews and case studies, with a common purpose to expand the current knowledge in this important area. Please note for IJMS's paper, clinical trials, and animal and cell testings are eligible only if they are strongly needed to support hypotheses or theories concerning structure–function correlations and are not suitable if no molecular aspects are considered.

Prof. Dr. Ari Zimran
Prof. Dr. Shoshana Revel-Vilk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lysosomal storage disorders
  • LSDs
  • lysosomal dysfunction
  • endoplasmic reticulum stress
  • altered lipid trafficking
  • autophagy
  • inflammation
  • enzyme therapy
  • substrate reduction
  • pharmacological chaperones
  • gene therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 6244 KiB  
Article
Targeting Glucosylceramide Synthase: Innovative Drug Repurposing Strategies for Lysosomal Diseases
by Giorgia Canini, Elena Mazzinelli, Giuseppina Nocca, Wanda Lattanzi and Alessandro Arcovito
Int. J. Mol. Sci. 2025, 26(5), 2195; https://doi.org/10.3390/ijms26052195 - 28 Feb 2025
Cited by 1 | Viewed by 512
Abstract
Sphingolipidoses, a subgroup of lysosomal storage diseases (LSDs), are rare and debilitating disorders caused by defects in sphingolipid metabolism. Despite advancements in treatment, therapeutic options remain limited. Miglustat, a glucosylceramide synthase EC 2.4.1.80 (GCS) inhibitor, is one of the few available pharmacological treatments; [...] Read more.
Sphingolipidoses, a subgroup of lysosomal storage diseases (LSDs), are rare and debilitating disorders caused by defects in sphingolipid metabolism. Despite advancements in treatment, therapeutic options remain limited. Miglustat, a glucosylceramide synthase EC 2.4.1.80 (GCS) inhibitor, is one of the few available pharmacological treatments; however, it is associated with significant adverse effects that impact patients’ quality of life. Drug repurposing offers a promising strategy to identify new therapeutic agents from approved drugs, expanding treatment options for rare diseases with limited therapeutic alternatives. This study aims to identify potential alternative inhibitors of GCS through a drug-repurposing approach, using computational and experimental methods to assess their therapeutic potential for sphingolipidoses. A library of approved drugs was screened using advanced computational techniques, including molecular docking, molecular dynamics simulations, and metadynamics, to identify potential GCS inhibitors. Promising candidates were selected for further in vitro validation to evaluate their inhibitory activity and potential as therapeutic alternatives to Miglustat. Computational screening identified several potential GCS inhibitors, with Dapagliflozin emerging as the most promising candidate. Experimental validation confirmed its efficacy, revealing a complementary mechanism of action to Miglustat while potentially offering a more favorable side effect profile. This study underscores the utility of computational and experimental methodologies in drug repurposing for rare diseases. The identification of Dapagliflozin as a potential GCS inhibitor provides a foundation for further preclinical and clinical evaluation, supporting its potential application in the treatment of sphingolipidoses. Full article
Show Figures

Graphical abstract

Review

Jump to: Research

21 pages, 2536 KiB  
Review
Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement
by Bram C. F. Veldman, Daphne H. Schoenmakers, Laura van Dussen, Mareen R. Datema and Mirjam Langeveld
Int. J. Mol. Sci. 2024, 25(17), 9752; https://doi.org/10.3390/ijms25179752 - 9 Sep 2024
Cited by 3 | Viewed by 2882
Abstract
Fabry disease (FD, OMIM #301500) is caused by pathogenic GLA gene (OMIM #300644) variants, resulting in a deficiency of the α-galactosidase A enzyme with accumulation of its substrate globotriaosylceramide and its derivatives. The phenotype of FD is highly variable, with distinctive disease features [...] Read more.
Fabry disease (FD, OMIM #301500) is caused by pathogenic GLA gene (OMIM #300644) variants, resulting in a deficiency of the α-galactosidase A enzyme with accumulation of its substrate globotriaosylceramide and its derivatives. The phenotype of FD is highly variable, with distinctive disease features and course in classical male patients but more diverse and often nonspecific features in non-classical and female patients. FD-specific therapies have been available for approximately two decades, yet establishing robust evidence for long-term effectiveness remains challenging. This review aims to identify the factors contributing to this lack of robust evidence for the treatment of FD with enzyme replacement therapy (ERT) (agalsidase-alfa and -beta and pegunigalsidase alfa) and chaperone therapy (migalastat). Major factors that have been identified are study population heterogeneity (concerning sex, age, phenotype, disease stage) and differences in study design (control groups, outcomes assessed), as well as the short duration of studies. To address these challenges, we advocate for patient matching to improve control group compatibility in future FD therapy studies. We recommend international collaboration and harmonization, facilitated by an independent FD registry. We propose a stepwise approach for evaluating the effectiveness of novel treatments, including recommendations for surrogate outcomes and required study duration. Full article
Show Figures

Figure 1

Back to TopTop